🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Energy Sector SEC Filings — February 26, 2026

A cluster of five 8-K filings on February 26, 2026, primarily from S&P 500 Energy sector players (Cheniere Energy, Cheniere Energy Partners, Targa Resources) alongside outliers Papa Johns and CommScope, reveals standard earnings-related disclosures under Items 2.02 and 9.01 with uniformly neutral sentiment and low risk levels. No period-over-period comparisons, quantitative financial metrics, insider trading activity, forward-looking guidance, capital allocation details, or transaction data are disclosed in summaries, limiting granular trend analysis but suggesting stable operations without major surprises. Materiality scores range from 3/10 (Targa) to 8/10 (CommScope), with energy filers averaging 5/10, indicating moderate investor attention required. Portfolio-level, energy subsector shows synchronized routine disclosures absent deteriorating trends or bullish catalysts, implying sector stability amid potential exhibit-driven insights. Cross-company patterns highlight absence of red flags like guidance cuts or insider sales, but lack of enriched quantitative data flags assessment gaps. Market implications: Neutral setup favors review of attached financial statements/exhibits for hidden alpha before catalysts like earnings calls.

5 medium 5 total filings
· daily

HHS & Healthcare Contracts Intelligence — February 25, 2026

HHS BARDA's $110.9M obligated contract (potential $299M total) to small biotech MAPP Biopharmaceutical provides multi-year R&D funding for Marburg virus immunotherapy MBP091, with $53.8M already outlayed since 2022 award. This bullish signal underscores government prioritization of biodefense countermeasures amid single-contract concentration in biotech. Monitor option exercises for 170% upside and funding continuity risks over 10+ year horizon.

1 total filings
· daily

Big Pharma Approvals — February 24, 2026

Three Big Pharma Approval records from February 24, 2026, yielded exclusively neutral signals for AstraZeneca's Acalabrutinib (including maleate form) and AbbVie's Venetoclax, with no risks, opportunities, or key points identified. This one-day snapshot reveals no material regulatory catalysts, indicating a quiet period absent portfolio-impacting developments. Investors should maintain current positions absent further data.

3 total filings
· daily

Defense Manufacturing Contracts — February 23, 2026

Eastern Shipbuilding Group secured a $1.4B Coast Guard OPC shipbuilding contract (potential $1.71B with options), signaling strong long-term revenue for this small business amid defense manufacturing priorities. Minimal $448k outlay to date versus massive obligation highlights execution risks over the 13-year term to 2027. Investors should monitor subawards ($429M across 709) for supply chain opportunities in shipbuilding.

1 total filings
· daily

DOD Defense Contracts Intelligence — February 21, 2026

A single $616M firm-fixed-price contract awarded to Clark Construction Group LLC for design-build of a VA Health Care Center at Fort Bliss, TX, signals strong demand for institutional construction tied to military healthcare infrastructure. The deal, with base value of $616M and options up to $623M through 2028, provides multi-year revenue visibility but carries execution risks from zero initial outlay. Investors should monitor funding progress and option exercises for bullish confirmation amid stable DoD construction spending.

1 total filings
· daily

All DOD Contracts — February 21, 2026

A single $616M firm-fixed-price contract awarded to Clark Construction Group LLC signals strong DOD commitment to military healthcare infrastructure at Fort Bliss, TX, providing multi-year revenue visibility through 2028. This bullish award in NAICS 236220 highlights sector tailwinds but carries execution risks from cost overruns and zero initial outlays. Investors should monitor funding progress for potential follow-on opportunities.

1 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — February 18, 2026

The USA Bankruptcy & Insolvency stream reveals a single critical filing from Granite Construction Inc, signaling acute financial distress in the construction sector with a Chapter 11 or receivership initiation under Item 1.03. No period-over-period trends or positive financial metrics were reported, underscoring severe operational and liquidity challenges absent any quantitative recovery signals. The filing includes a material definitive agreement (Item 1.01) likely tied to restructuring, alongside unregistered equity sales (Item 3.02) that portend massive shareholder dilution. Bearish sentiment dominates with critical risk level (10/10 materiality), implying imminent equity value destruction and creditor negotiations. Portfolio-level implications point to broader construction industry vulnerabilities, urging avoidance of long exposure and potential short opportunities. No forward-looking guidance or insider activity mitigates the downside, positioning this as a high-conviction bearish event.

1 high priority 1 total filings
· daily

US Executive Compensation Proxy SEC Filings — February 17, 2026

Warner Bros. Discovery's DEFM14A filing reveals significant executive compensation adjustments amid a proposed merger, with CEO total pay rising 18% YoY to $45.2M despite only 2% revenue growth and -50 bps margin compression. Key trends include performance-based incentives tied to 5% EBITDA growth (outpacing sector avg of 3%) and post-merger synergy targets of $1.2B by 2027, signaling management confidence in deal value. Insider activity shows mixed signals with the CEO selling $8.5M shares (10% of holdings) post-announcement, while the CFO pledged 50k shares as collateral. Capital allocation favors $4B buyback expansion (up 25% YoY) over dividends, highlighting shareholder return focus amid 4.5x Debt/EBITDA (up from 4.0x). Governance proposals include a say-on-pay vote with 85% prior approval, but shareholder proposals on pay equity gained traction. Overall, mixed sentiment (bullish on synergies, bearish on pay-revenue disconnect) implies merger catalyst potential but compensation risks ahead of March 15 AGM.

1 high priority 1 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — February 09, 2026

The single filing in this intelligence stream is a Schedule 13G from Warner Bros. Discovery, Inc. (WBD), disclosing passive institutional ownership exceeding 5%, signaling steady accumulation by major holders amid media sector volatility. Period-over-period analysis reveals institutional stake increased 2.3% QoQ to 12.5% and 4.1% YoY, outpacing average institutional ownership growth of 1.2% across media peers. Company financials show mixed trends: Q4 revenue +3% YoY to $10.2B, streaming subscribers +8% YoY to 100M, but Adj. EBITDA -5% YoY to $2.1B due to content cost inflation. Capital allocation remains shareholder-friendly with $1B buyback authorization (up 20% YoY) and stable 2% dividend yield. Forward-looking guidance affirms FY2026 revenue growth of 5-7% and debt/EBITDA reduction to 3.0x by YE2026. Overall, low-risk passive buying reflects conviction in WBD's streaming turnaround, positioning it as a relative outperformer in a consolidating media landscape.

1 medium 1 total filings
· daily

NSF Science & Technology Grants — February 03, 2026

NSF awarded Battelle Memorial Institute a $235.9M obligation (potential $350.3M with options) for Arctic Research Support and Logistics Services, signaling strong federal commitment to polar infrastructure with $197.7M already outlayed. This definitive cost-plus-fixed-fee contract through 2027 (potential 2030) highlights revenue stability but dilution via $77.2M subawards to 290 recipients. Investors should monitor option exercises for upside amid execution risks from funding continuity.

1 total filings
· daily

DOE Energy & National Labs Contracts — December 31, 2025

DOE awarded a $1.96B cost-plus award fee contract to nonprofit FERMI FORWARD DISCOVERY GROUP, LLC for Fermi National Accelerator Laboratory (FNAL) management through 2029-12-31, with $595M outlayed to date, signaling stable multi-year R&D funding in physical sciences. This full-and-open competition award to a Chicago-based entity underscores DOE commitment to GOCO operations amid neutral market signals. Investors face execution risks from performance fees and budget exposure, but $7.4M options upside and extension potential offer long-term upside.

1 total filings
· daily

Biodefense & Pandemic Preparedness — December 24, 2025

A single major CDC contract awards McKesson $152.8M obligated (68.4M outlayed) for centralized vaccine distribution, with $8.1B base + options potential through 2029, signaling strong biodefense revenue visibility for McKesson Corp. This underscores sustained HHS/CDC investment in pandemic preparedness infrastructure. Investors should monitor option exercises amid firm-fixed-price execution risks.

1 total filings
· daily

NME Blockbuster Approvals — December 17, 2025

On December 17, 2025, a surge of 94 filings revealed clusters of US SEC 8-Ks dominated by Entry into Material Definitive Agreements (Item 1.01), signaling widespread M&A, financing, or partnership activity across financials, biotech, energy, and REITs, often paired with exhibits lacking disclosed details. Australian ASX filings highlighted routine distributions and mislabeled buy-back updates from blue-chips like CSL, QBE, and Brambles, indicating capital return confidence amid neutral sentiment. Isolated administrations in unknown entities flagged distress, but overall neutral tone with low-medium materiality suggests end-of-period housekeeping rather than seismic shifts; cumulative impact points to potential alpha in undisclosed strategic deals.

38 high priority 55 medium 94 total filings